Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens

Naoe Goto, Hisashi Tsurumi, Senji Kasahara, Nobuhiro Kanemura, Takeshi Hara, Ichiro Yasuda, Masahito Shimizu, Nobuo Murakami, Michio Sawada, Toshiki Yamada, Masao Takemura, Mitsuru Seishima, Yusuke Kito, Tsuyoshi Takami, Hisataka Moriwaki

研究成果: ジャーナルへの寄稿学術論文査読

25 被引用数 (Scopus)

抄録

Background: We have previously reported that serum interleukin-18 (IL-18) concentration predicted the clinical outcome of patients with aggressive non-Hodgkin's lymphoma treated with cyclophosphamide, doxorubicin, vincristine, and prednisolone (CHOP). When rituximab (R) was added to this regimen, the prognosis of diffuse large B-cell lymphoma (DLBCL) was markedly improved. Patients and Methods: In this study, we re-evaluated the prognostic significance of serum IL-18 in 227 DLBCL patients. Seventy-three patients received CHOP before R-era, and 154 patients received rituximab-cyclophosphamide, doxorubicin, vincristine, and prednisolone (R-CHOP) recently. Result: Four-year overall survival (4-yr OS) rates for patients in CHOP group with IL-18≥720pg/mL and <720pg/mL were 8.2% and 67.3% (P<0.0001), respectively, and 4-yr OS rates with IL-18≥590 and <590pg/mL in R-CHOP group were 53.4% and 77.8% (P=0.0008), respectively. Multivariate analysis revealed that serum IL-18 correlated most significantly with OS and progression-free survival (PFS) in both groups (OS: P<0.0001, PFS: P<0.0001, in CHOP group; OS: P=0.0147, PFS: P=0.0084 in R-CHOP group). The high serum IL-18 patients with poor prognostic group in revised IPI or with non-germinal center B-cell phenotype had a very poor prognosis. Conclusion: Serum IL-18 might be a powerful prognostic factor for DLBCL in R-era.

本文言語英語
ページ(範囲)217-227
ページ数11
ジャーナルEuropean Journal of Haematology
87
3
DOI
出版ステータス出版済み - 09-2011
外部発表はい

All Science Journal Classification (ASJC) codes

  • 血液学

フィンガープリント

「Serum interleukin-18 level is associated with the outcome of patients with diffuse large B-cell lymphoma treated with CHOP or R-CHOP regimens」の研究トピックを掘り下げます。これらがまとまってユニークなフィンガープリントを構成します。

引用スタイル